Greenspring Advisors LLC increases its position in Eli Lilly and Company (NYSE:LLY)

Greenspring Advisors LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 14.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,490 shares of the company’s stock after purchasing an additional 190 shares during the quarter. Eli Lilly and Company makes up about 0.3% of Greenspring Advisors LLC’s portfolio, making the stock its 22nd largest position. Greenspring Advisors LLC’s holdings in Eli Lilly and Company were worth $1,349,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after purchasing an additional 1,133,810 shares during the period. Capital World Investors boosted its stake in Eli Lilly and Company by 0.3% in the fourth quarter. Capital World Investors now owns 26,949,773 shares of the company’s stock valued at $15,709,466,000 after buying an additional 89,720 shares in the last quarter. Norges Bank acquired a new stake in Eli Lilly and Company in the fourth quarter valued at about $5,992,890,000. Capital Research Global Investors boosted its holdings in Eli Lilly and Company by 6.0% in the first quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after purchasing an additional 453,939 shares during the period. Finally, Capital International Investors raised its position in Eli Lilly and Company by 5.1% in the first quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock valued at $5,424,243,000 after buying an additional 335,560 shares in the last quarter. 82.53% of shares are owned by institutional investors and hedge funds.

Changes in Analyst Ratings

LLY has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Berenberg Bank raised their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Argus boosted their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Finally, BMO Capital Markets upped their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The company has a consensus rating of “Moderate Buy” and an average target price of $956.88, according to MarketBeat.

Get the latest stock analysis on Eli Lilly and Company

Eli Lilly and Company traded down 0.3%

Eli Lilly and Company stock traded down $2.47 during mid-day trading on Monday, hitting $919.65. The company’s stock had a trading volume of 803,238 shares, compared to its average volume of 3,083,729. The stock’s fifty day moving average is $878.93, and its two hundred day moving average is $806.28. The company has a current ratio of 1.35, a quick ratio of 1.03, and a debt-to-equity ratio of 1.90. The firm has a market cap of $874.04 billion, a PE ratio of 135.44, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $966.10.

Eli Lilly and Company announces dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a dividend of $5.20 on an annualized basis and a dividend yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15. Eli Lilly and Company’s payout ratio is 76.58%.

Insider buying and selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the transaction, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,214,704 shares of company stock worth $1,066,841,316. 0.13% of shares are currently owned by insiders.

Eli Lilly and Company Profile

(Free report)

Eli Lilly and Company discovers, develops and markets human pharmaceutical products worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R and Humulin U-500 for diabetes; Jardiance, Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured stories

Get news and reviews for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.